BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Thursday reported a loss of $36.5 million in its third quarter.

The Bedford, Massachusetts-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring gains, were 26 cents per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The biotechnology company posted revenue of $15.4 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $17.7 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OCUL at https://www.zacks.com/ap/OCUL